Precision Medicine Portfolio Update
Filed with ASX · · 4 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallMelbourne (Australia) and Indianapolis, IN (U.S.) – 22 December 2025. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides a precision medicine portfolio update in relation to: • TLX591-CDx (Illuccix® in approved jurisdictions, 68Ga-PSMA-11): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China. • TLX101-CDx (Pixclar
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- ProstACT Global Study Status
- Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
- 1st Patient Dosed in ProstACT Global Randomized Tx Expansion
- Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held
- ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
Later from Telix Pharmaceuticals
- Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
- First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
- Chinese NMPA Accepts New Drug Application for Illuccix
- Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
- Telix Achieves FY25 Guidance - US$804M, Q4 Growth
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals